Law Amanda J, Harrison Paul J
Department of Psychiatry, University of Oxford, Neurosciences Building, Warneford Hospital, OX3 7JX, Oxford, UK.
J Psychiatr Res. 2003 Nov-Dec;37(6):487-99. doi: 10.1016/s0022-3956(03)00075-x.
Alterations in the density and size of pyramidal neurons in the prefrontal cortex have been described in schizophrenia and mood disorder. However, the changes are generally modest and have not always been replicated. We investigated the possibility that specific pyramidal neuron sub-populations, defined by their immunoreactivity with the anti-neurofilament antibodies SMI32, N200, and FNP7, are differentially affected in these disorders. First, we assessed the distribution and characteristics of pyramidal neurons labelled by the antibodies in the human dorsolateral prefrontal cortex (Brodmann areas 9, 32, 46), using single and double label immunocytochemistry and immunofluorescence. Three largely separate sub-populations of pyramidal neurons were identified, although with more substantial overlap between SMI32- and FNP7-positive neurons in lamina V. We then determined the density, size and shape of the three pyramidal neuron sub-populations in area 9 in patients with schizophrenia, bipolar disorder, or major depressive disorder, compared to controls (n=15 in each group). We found a lower density of lamina III N200-positive neurons in major depressive disorder than in schizophrenia or bipolar disorder. There were no other overall differences in neuronal density, or in neuronal size or shape, although a planned secondary analysis supported the previously reported decrease of neuronal size in lamina V in bipolar disorder. In summary, our study illustrates a conceptual and methodological approach which may be of value for investigating the differential neuropathological involvement of pyramidal neuron sub-populations. However, we found no clear evidence that the prefrontal neuropathology of schizophrenia or mood disorders preferentially affects SMI32-, N200- or FNP7-immunoreactive pyramidal neurons.
精神分裂症和心境障碍患者前额叶皮质中锥体神经元的密度和大小存在改变。然而,这些变化通常较小,且并非总能重复出现。我们研究了由抗神经丝抗体SMI32、N200和FNP7免疫反应性所定义的特定锥体神经元亚群在这些疾病中受到不同影响的可能性。首先,我们使用单标和双标免疫细胞化学及免疫荧光技术,评估了抗体标记的锥体神经元在人背外侧前额叶皮质(布罗德曼区9、32、46)中的分布和特征。尽管V层中SMI32阳性神经元和FNP7阳性神经元之间有更多实质性重叠,但仍鉴定出了三个基本分离的锥体神经元亚群。然后,我们比较了精神分裂症、双相情感障碍或重度抑郁症患者与对照组(每组n = 1)9区中三个锥体神经元亚群的密度、大小和形状。我们发现,重度抑郁症患者III层N200阳性神经元的密度低于精神分裂症或双相情感障碍患者。尽管一项计划中的二次分析支持了先前报道的双相情感障碍患者V层神经元大小减小,但在神经元密度、大小或形状方面没有其他总体差异。总之,我们的研究说明了一种概念和方法,可能对研究锥体神经元亚群的不同神经病理学参与情况有价值。然而,我们没有发现明确证据表明精神分裂症或心境障碍的前额叶神经病理学优先影响SMI32、N200或FNP7免疫反应性锥体神经元。